Biohit Oyj (BIOBV.HE)
EUR 2.23
(-2.19%)
EUR 2.23
(-2.19%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 13.07 Million EUR | 19.62% |
| 2022 | 10.95 Million EUR | 16.99% |
| 2021 | 9.36 Million EUR | 31.42% |
| 2020 | 7.12 Million EUR | -29.14% |
| 2019 | 10.05 Million EUR | 1.22% |
| 2018 | 9.93 Million EUR | 10.6% |
| 2017 | 8.97 Million EUR | 9.57% |
| 2016 | 8.19 Million EUR | 35.43% |
| 2015 | 6.05 Million EUR | 38.69% |
| 2014 | 4.36 Million EUR | 26.39% |
| 2013 | 3.45 Million EUR | 68.55% |
| 2012 | 2.04 Million EUR | -94.87% |
| 2011 | 39.92 Million EUR | -0.3% |
| 2010 | 40.04 Million EUR | 13.23% |
| 2009 | 35.36 Million EUR | 1.61% |
| 2008 | 34.8 Million EUR | 6.27% |
| 2007 | 32.75 Million EUR | 4.28% |
| 2006 | 31.4 Million EUR | 9.59% |
| 2005 | 28.66 Million EUR | 7.33% |
| 2004 | 26.7 Million EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 3.7 Million EUR | 0.0% |
| 2024 Q1 | 3.7 Million EUR | -43.94% |
| 2023 FY | 13.1 Million EUR | 19.62% |
| 2023 Q1 | 3.25 Million EUR | -32.29% |
| 2023 Q2 | 6.5 Million EUR | 100.0% |
| 2023 Q3 | 3.28 Million EUR | -49.42% |
| 2023 Q4 | 6.6 Million EUR | 100.73% |
| 2022 Q3 | 2.42 Million EUR | -60.24% |
| 2022 Q1 | 3.05 Million EUR | -42.45% |
| 2022 FY | 10.95 Million EUR | 16.99% |
| 2022 Q4 | 4.8 Million EUR | 97.9% |
| 2022 Q2 | 6.1 Million EUR | 100.0% |
| 2021 FY | 9.36 Million EUR | 31.42% |
| 2021 Q4 | 5.3 Million EUR | 97.72% |
| 2021 Q1 | 2 Million EUR | -51.22% |
| 2021 Q3 | 2.68 Million EUR | -32.99% |
| 2021 Q2 | 4 Million EUR | 100.0% |
| 2020 Q3 | 2.06 Million EUR | -31.28% |
| 2020 FY | 7.12 Million EUR | -29.14% |
| 2020 Q2 | 3 Million EUR | 100.0% |
| 2020 Q1 | 1.5 Million EUR | -70.59% |
| 2020 Q4 | 4.09 Million EUR | 98.88% |
| 2019 Q3 | 2.52 Million EUR | -49.48% |
| 2019 Q4 | 5.1 Million EUR | 101.9% |
| 2019 FY | 10.05 Million EUR | 1.22% |
| 2019 Q2 | 5 Million EUR | 100.0% |
| 2019 Q1 | 2.5 Million EUR | -0.62% |
| 2018 FY | 9.93 Million EUR | 10.6% |
| 2018 Q3 | 2.51 Million EUR | 2.67% |
| 2018 Q2 | 2.45 Million EUR | 0.0% |
| 2018 Q1 | 2.45 Million EUR | 0.43% |
| 2018 Q4 | 2.51 Million EUR | 0.0% |
| 2017 Q3 | 2.43 Million EUR | 19.0% |
| 2017 Q1 | 2.04 Million EUR | -6.71% |
| 2017 Q4 | 2.43 Million EUR | 0.0% |
| 2017 FY | 8.97 Million EUR | 9.57% |
| 2017 Q2 | 2.04 Million EUR | 0.0% |
| 2016 Q3 | 2.19 Million EUR | 15.66% |
| 2016 Q1 | 1.9 Million EUR | 51.88% |
| 2016 FY | 8.19 Million EUR | 35.43% |
| 2016 Q4 | 2.19 Million EUR | 0.0% |
| 2016 Q2 | 1.9 Million EUR | 0.0% |
| 2015 Q3 | 1.3 Million EUR | -43.48% |
| 2015 Q2 | 2.3 Million EUR | 91.67% |
| 2015 Q1 | 1.2 Million EUR | 3.18% |
| 2015 Q4 | 1.25 Million EUR | -3.77% |
| 2015 FY | 6.05 Million EUR | 38.69% |
| 2014 Q1 | 900 Thousand EUR | 19.68% |
| 2014 FY | 4.36 Million EUR | 26.39% |
| 2014 Q4 | 1.16 Million EUR | -3.08% |
| 2014 Q3 | 1.2 Million EUR | 9.09% |
| 2014 Q2 | 1.1 Million EUR | 22.22% |
| 2013 Q3 | 1.3 Million EUR | 62.5% |
| 2013 Q4 | 752 Thousand EUR | -42.15% |
| 2013 Q1 | 600 Thousand EUR | -7.41% |
| 2013 Q2 | 800 Thousand EUR | 33.33% |
| 2013 FY | 3.45 Million EUR | 68.55% |
| 2012 FY | 2.04 Million EUR | -94.87% |
| 2012 Q3 | 400 Thousand EUR | 0.0% |
| 2012 Q2 | 400 Thousand EUR | 0.0% |
| 2012 Q4 | 648 Thousand EUR | 62.0% |
| 2012 Q1 | 400 Thousand EUR | -95.84% |
| 2011 Q4 | 9.62 Million EUR | -1.82% |
| 2011 Q1 | 10.4 Million EUR | -6.68% |
| 2011 Q2 | 10.2 Million EUR | -1.92% |
| 2011 Q3 | 9.8 Million EUR | -3.92% |
| 2011 FY | 39.92 Million EUR | -0.3% |
| 2010 Q2 | 9.9 Million EUR | 5.32% |
| 2010 Q3 | 9.6 Million EUR | -3.03% |
| 2010 Q1 | 9.4 Million EUR | -8.44% |
| 2010 Q4 | 11.14 Million EUR | 16.08% |
| 2010 FY | 40.04 Million EUR | 13.23% |
| 2009 Q1 | 8.3 Million EUR | 0.0% |
| 2009 FY | 35.36 Million EUR | 1.61% |
| 2009 Q4 | 10.26 Million EUR | 26.74% |
| 2009 Q3 | 8.1 Million EUR | -6.9% |
| 2009 Q2 | 8.7 Million EUR | 4.82% |
| 2008 FY | 34.8 Million EUR | 6.27% |
| 2007 FY | 32.75 Million EUR | 4.28% |
| 2006 FY | 31.4 Million EUR | 9.59% |
| 2005 FY | 28.66 Million EUR | 7.33% |
| 2004 FY | 26.7 Million EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Herantis Pharma Oyj | - EUR | -Infinity% |
| Nanoform Finland Oyj | 2.56 Million EUR | -409.491% |